In Biosimilar Guidelines - Feb 17, 2014

Guidelines on Similar Biologics:
Regulatory Requirement for MA in India
Feb 17, 2014
IPMG Lupin Class C 1

Introduction
• prepared by Central Drugs Standard Control Organization (CDSCO)
and the Department of Biotechnology (DBT)
• Guidelines address:
– Regulatory pathway regarding manufacturing process and quality
aspects for similar biologics
– Pre-market regulatory requirements including comparability
exercise for quality, preclinical and clinical studies and post market
regulatory requirements for similar biologics
– To ensure comparable safety, efficacy and quality of a similar
biologic to an authorized reference biologic.
Introduction
Various applicable guidelines:
• Recombinant DNA Safety Guidelines, 1990
• Guidelines for generating preclinical and clinical data for rDNA vaccines,
• diagnostics and other biologicals, 1999
• CDSCO guidance for industry, 2008:

– Submission of Clinical Trial Application for Evaluating Safety and Efficacy
– Requirements for permission of New Drugs Approval
– Post approval changes in biological products: Quality, Safety and Efficacy Documents
– Preparation of the Quality Information for Drug Submission for New Drug Approval:
Biotechnological/Biological Products
• Guidelines and Handbook for Institutional Biosafety Committees (IBSCs), 2011

Competent Authorities
• Review Committee on Genetic Manipulation (RCGM)
– Functions in Department of Biotechnology (DBT)
– Authorizes import/export for R&D to preclinical evaluation
• Genetic Engineering Appraisal Committee (GEAC)

– Part of Environment & Forest
– Approves large scale use of GMO, their products in R&D, industry & environment release
and filed applications
• Central Drugs Standard Control Organization (CDSCO)

– Headed by Drug Controller General of India (DGCI)
– Grant/approval of import/export license & clinical trials
– Grant/approval of marketing & manufacturing
– CDSCO & state FDA provide license to manufacture biosimilar in India

Reference Biologic
• The reference biologic should be licensed in India and should be innovator product. The
reference biologic should be licensed based on a full safety, efficacy and quality data.
• In case the reference biologic is not marketed in India, the reference biologic should have been
licensed and widely marketed for 4 years post approval in innovator jurisdiction in a country
with well established regulatory framework. In case no medicine or only palliative therapy is
available or in national healthcare emergency, this period of 4 years may be reduced or waived
off.
• The same reference biologic should be used throughout the studies supporting the safety,
efficacy and quality of the product (i.e. in the development programme for the similar biologic)
• The dosage form, strength and route of administration of the similar biologic should be the
same as that of the reference biologic.
• The active substance (active ingredient) of the reference biologic and that of the similar
biologic must be shown to be similar
Manufacturing Process
• For review of manufacturing process at preclinical submission stage, the data
should include a complete description of:
– The manufacturing process from development and characterization of cell
banks,
– Stability of clone
– cell culture/ fermentation
– harvest
– excipients
– formulation
– purification
– primary packaging interactions (if different from reference biologic)

Molecular Biology Considerations:
• The details regarding host cell cultures (including viral clearance), vectors, gene sequences, promoters
etc. used in the production with appropriate drawings/figures
• The details of post-translational modifications if any
Fermentation Process Development:
• At least three batches of reproducible fermentation data at pilot scale
• Fermentation process should be carried out in controlled and monitored environment.
• Details of fermentation kinetics data from a representative batch indicating cell growth, product
formation, pH, temperature, dissolved oxygen, major nutrient consumption pattern and agitation
rate.
• Concentration to be defined in terms of product/litre, yield and volumetric productivity.
• Data to verify that the specific protein yield (amount of protein per unit cell mass) remains constant
for all fermentation batches.
• Demonstrate that the overall productivity is reproducible and scalable.

Downstream Process Development
• Steps involved in purification of protein.
• Batch size for protein purification.
• Description of each unit operation step during purification and recovery of protein along
with quantitative recovery of product at each stage.
• Describe the quality of the refolded protein if the starting material is aggregated or from
inclusion bodies and include details of the refolding process, specific activity at different
doses, dose response curve, stability data and confirmation of solubility and absence of
aggregation.
• Consistency of recovery in 3 consecutive batches of purification from 3 independent batches
of fermentation

For Clinical trials, Additional data needed:
• Detailed description of the drug substance and drug product processes
• Critical quality attributes of the product
• Manufacturing process controls
• Critical process parameters
• Stability data
• Comparability of product manufactured at clinical scale against reference biologic
• Data from consistency batches and/or process validation batches as applicable

Quality Based Considerations for Similar Biologics
• Analytical methods
• Product Characterization
• Specifications
• Stability

Data Requirements for Preclinical Studies
• The applicant should submit the data generated along with the following basic clinical
information and preclinical study protocols to RCGM for obtaining permission
• Approval from Institutional Biosafety Committee (IBSC) and Institutional Animal Ethics
Committee (IAEC) should be submitted.
• Proposed toxicology study details should be submitted
• GLP certification of proposed facility should also be provided.
• The toxicology studies should be initiated after the approval of RCGM

Data Requirements for Preclinical Studies
Basic information about the reference biologic
• Information about the drug, route of administration, absorption and elimination rate, therapeutic
index, dose, vehicle, mode of administration, dose response etc.
• Bioequivalence range, if available.
• Tissue-specific localization , if available.
• Available toxicity data on reference biologic.
• Mode of action.
Basic information about the similar biologic

• Known / proposed clinical use
• Target population (Age, sex, pregnancy, lactating, children etc.)
• Dosage (frequency and intervals) –units
• Route / alternate routes of administration
• Final formulation + adjuvants, additives etc. - Toxicology data of adjuvants
• Diluents
• Presentation e.g. pre filled syringe
Preclinical Studies
• Pharmacodynamic Studies
– In vitro studies should be established
– In vivo studies elauation
• Toxicological studies
– In vivo studies, at least 1 repeat dose toxicity study in a relevant species is
required. Duration should be not less than 28 days with recovery period of 14
days
– Animal models, scientific justification should be provided.
– Route of administration, only the intended route should be included
– Dose should be calculated based on the therapeutic dose of reference biologic

Preclinical Studies
Final report of the study should reflect:
• RCGM approval of protocol and test center
• IBSC approval of report
• IAEC approval for animal use and for the procedures
• QA statement
• Signatures of study director and all investigators who were involved in the study
• All quality analytical reports on the test material and vehicle
• Animal feed and animal health certifications
• Protocol deviations if any
• Discussion on the results
• Individual animal data, summary data and any other data like computer analysis outputs etc
• Conclusion

Data Requirements for Clinical Trial Application
• Pharmacokinetic Studies (Phase I):
– On healthy volunteers
– Half life
– Linearity of PK parameters
– Endogenous levels and diurnal variations of similar biologic under study (where applicable)
– Conditions and diseases to be treated

– Route(s) of administration, and
– Indications
Appropriate design considerations can be combined into single dose or multiple dose studies with
adequate justification. These design considerations include:
– Single dose, comparative, PK studies
– Parallel arm or
– Cross over
– Multiple dose, comparative parallel arm steady state PK studies

Data Requirements for Clinical Trial Application
• Pharmacodynamic Studies
– In relevant population
– Can be a part of phase III clinical trials
• Confirmatory Safety and Efficacy Study

– Information to establish comparative safety and efficacy in relevant patient population
– Can be waived off

• Safety and Immunogenicity Data
– Both pre-approval and post-approval assessment of safety is desired
• Extrapolation of Efficacy and Safety Data to Other Indications can be done if:
– Similarity with respect to quality has been proven to reference biologic
– Similarity with respect to preclinical assessment has been proven to reference biologic
– Clinical safety and efficacy is proven in one indication
– Mechanism of action is same for other clinical indications

– Involved receptor(s) are same for other clinical indications

Data Requirements for Market Authorization Application
• Application should be submitted for market authorization as per CDSCO guidance document
for industry, 2008
• Cases where commercial manufacturing is performed either at a different scale and/or with
a different process as compared to that used for manufacturing phase III clinical trial
batches, then information on comparability of quality needs to be additionally submitted

Post-Market Data for Similar Biologics
• Risk management plan should be submitted which should include:
– Pharmacovigilance Plan
– Adverse Drug Reaction (ADR) Reporting
– Post Marketing Studies (PMS)

Application Forms

Physicochemical and biological characterization of nucleic acid
based recombinant products

Physicochemical and biological characterization of nucleic acid
based recombinant products

Physicochemical and biological characterization of therapeutic
proteins

Physicochemical and biological characterization of antibodies

Physicochemical and biological characterization of antibodies

Thank you

In Biosimilar Guidelines - Feb 17, 2014

Uploaded by

Copyright:

Available Formats

In Biosimilar Guidelines - Feb 17, 2014

Uploaded by

Document Information

Original Description:

Original Title

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

In Biosimilar Guidelines - Feb 17, 2014

Uploaded by

Copyright:

Available Formats

Guidelines on Similar Biologics:

Regulatory Requirement for MA in India

Feb 17, 2014

IPMG Lupin Class C 1

• diagnostics and other biologicals, 1999

• CDSCO guidance for industry, 2008:

• Guidelines and Handbook for Institutional Biosafety Committees (IBSCs), 2011

IPMG Lupin Class C 3

– Authorizes import/export for R&D to preclinical evaluation

• Genetic Engineering Appraisal Committee (GEAC)

• Central Drugs Standard Control Organization (CDSCO)

– Grant/approval of import/export license & clinical trials

– Grant/approval of marketing & manufacturing

– CDSCO & state FDA provide license to manufacture biosimilar in India

– cell culture/ fermentation

– primary packaging interactions (if different from reference biologic)

IPMG Lupin Class C 6

• The details of post-translational modifications if any

Fermentation Process Development:

• At least three batches of reproducible fermentation data at pilot scale

• Fermentation process should be carried out in controlled and monitored environment.

• Concentration to be defined in terms of product/litre, yield and volumetric productivity.

• Demonstrate that the overall productivity is reproducible and scalable.

IPMG Lupin Class C 8

IPMG Lupin Class C 9

IPMG Lupin Class C 10

IPMG Lupin Class C 11

Basic information about the similar biologic

IPMG Lupin Class C 13

IPMG Lupin Class C 14

– Conditions and diseases to be treated

IPMG Lupin Class C 15

• Confirmatory Safety and Efficacy Study

– Can be waived off

– Mechanism of action is same for other clinical indications

IPMG Lupin Class C 16

IPMG Lupin Class C 17

IPMG Lupin Class C 18

IPMG Lupin Class C 19

IPMG Lupin Class C 23

IPMG Lupin Class C 24

IPMG Lupin Class C 25

IPMG Lupin Class C 26

IPMG Lupin Class C 27

IPMG Lupin Class C 28

You might also like